The ratio of LC3 II/I was significantly upregulated and the degradation of SQSTM/p62 was significantly hampered in the DMSO-treated AD group, compared with the CTRL group (p < 0.01; Figures 5D,E). This evidence concerns the gene SQSTM1 and Alzheimer disease.